Verified employee & interview reviews

Strand Life Sciences Reviews

Bengaluru, Karnataka

4.0/ 5

3 reviews

Strand Life Sciences (formerly known as Strand Genomics) is a prominent Indian bioinformatics, computational biology, and genomics research company headquartered in Bangalore, Karnataka. Established in October 2000 by a group of distinguished professors from the Indian Institute of Science (IISc)—Vijay Chandru, Ramesh Hariharan, Swami Manohar, and V. Vinay—the company stands as an early and highly successful example of academic entrepreneurship in India. In 2021, Reliance Industries Limited, through its subsidiary Reliance Strategic Business Ventures, acquired a controlling stake in the company, integrating it as a key subsidiary within its broader healthcare and life sciences portfolio. Over its 25-year history, Strand Life Sciences has evolved from an early bioinformatics start-up into a global leader in precision medicine, specialized diagnostics, and multiomics research. The company seamlessly bridges the gap between advanced software engineering and laboratory assays. It operates a world-class infrastructure that includes the Strand Genomics Diagnostics & Research Centre, featuring the only College of American Pathologists (CAP) and NABL-accredited genomics laboratory in South Asia. Through an extensive network of over 15 partner laboratories across major Indian metros and emerging cities, Strand delivers a comprehensive menu of routine and highly specialized genetic tests. The core operations of Strand Life Sciences are broadly divided into clinical diagnostics, bioinformatics software development, and pharmaceutical research services. In the clinical segment, the company provides advanced genetic testing across reproductive health, rare diseases, genomic wellness, and oncology, offering critical solutions like carrier screening, exome sequencing, and liquid biopsies. Strategically, Strand has developed proprietary software platforms that are utilized by clinical and research laboratories worldwide. Prominent among these are Strand NGS (formerly Avadis NGS), a comprehensive platform for next-generation sequencing data analysis, and StrandOmics, a specialized platform designed for automated variant interpretation, classification, and clinical reporting. Furthermore, Strand is a trusted B2B partner for global instrument manufacturers, diagnostics firms, and top-tier pharmaceutical companies across North America, Europe, and Asia. It delivers tailored bioinformatics solutions to accelerate drug discovery, translational medicine, and clinical trials. This includes offering advanced capabilities in data mining, predictive modeling, single-cell and spatial transcriptomics, and real-world data harmonization. Financially stable and scaling under the leadership of co-founder and CEO Dr. Ramesh Hariharan, alongside a multidisciplinary team of over 300 to 500 highly trained professionals, Strand has completed hundreds of complex genomic projects and written millions of lines of code. Driven by core values of innovation, collaboration, and absolute clinical integrity, Strand Life Sciences continues to advance low-cost, high-throughput molecular profiling to make global precision medicine and targeted therapies accessible and actionable for all.